ELDN Company Profile and Key Details

The stock is currently mid-range between its 52-week high and low $1.35 and $4.60. With a market capitalization of about $214.58 million, Eledon Pharmaceuticals, Inc. is classified as a micro-cap and shows market-like volatility (beta ~0.94). Key stats such as the average daily volume over the past year has been around 1.29 million shares, volume is running light vs its 52-week average. Headquartered in Irvine, CA, Eledon Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David-Alexandre C. Gros, the company employs approximately 33 people and listed since September 17, 2014. Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation.

Eledon Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.27. This means the shares are trading above this model’s fair value.

Eledon Pharmaceuticals, Inc. has 81.26 million shares outstanding. The public float is 74.60 million shares, elevated short interest at 8.05% of float. This equals 6.21 million shares. The short ratio is 5.23 days. Institutional investors hold 60.56% of the float. Insiders own 1.09%. Harrison Seth Loring holds 7.91 million shares, Novartis Bioventures Ltd has 4.49 million shares and Apple Tree Partners II - Annex, L.P. has 3.57 million shares.

Eledon Pharmaceuticals, Inc. generated EPS of -$1.20 over the past year. Five-year average earnings growth is 50.24%. Wall Street analysts project EPS growth of -3.99% annually over the next five years. The latest quarter delivered EPS of -$0.19. The next quarter is forecast at -$0.20. Next year's EPS is expected at $26.04. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $8.00. The high target offers 331.65% upside. The low target suggests 187.77% downside. The mean target is $10.00. This offers 259.71% upside. Eledon Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 20.25%. The prior quarter beat by 8195.45%. Over the last six quarters, Apple has recorded several small beats. These include -71.43% in May 14, 2025.

Eledon Pharmaceuticals, Inc. trades at a P/E ratio of -2.81, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 4.38 trading at moderately above to book value. The P/FCF stands at -2.9, also below market averages.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) shares are up 46.36% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Eledon Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -2.81. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $13.62, suggesting 389.93% upside. Our AI forecast model points to short-term weakness (-17.27% over two weeks), a medium-term fall (-0.72% over three months), and a longer-term gain (600.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Eledon Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.27%, with price expected at $2.30 by September 25, 2026, within a range of $2.18 to $2.42 3-Month Outlook: Projected fall of -0.72%, reaching $2.76 by December 10, 2026, with a range of $2.57 to $2.92. 1-Year Outlook: Projected gain of 600.0%, with price at $19.46 by September 10, 2027, within a range of $21.00 to $23.56.